McCoy Andrew C, Kliethermes Beth, Zhang Ke, Qin Wenyi, Sticca Robert, Bouton Michael, Sauter Edward R
Department of Surgery, University of North Dakota School of Medicine, Grand Forks, ND, USA.
BMC Res Notes. 2011 May 26;4:152. doi: 10.1186/1756-0500-4-152.
In preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. Blood from 30 premenopausal women was collected and serum extracted prior to their undergoing breast biopsy to assess a suspicious lesion found on imaging or physical examination. Based on biopsy results, the serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical hyperplasia or lobular carcinoma in situ), or benign.
Serum from women with cancer and precancer (p = .0009) had lower MIS levels than serum from women with benign disease.
Our findings provide preliminary evidence for MIS being associated with current breast cancer risk, which should be validated in a larger population.
在临床前研究中，苗勒管抑制物质（MIS）对乳腺癌具有保护作用。我们的目的是确定血清MIS浓度是否与癌性或癌前病变相关。在30名绝经前女性接受乳房活检之前采集血液并提取血清，以评估影像学检查或体格检查中发现的可疑病变。根据活检结果，血清标本分为癌症（浸润性癌或导管原位癌）、癌前病变（非典型增生或小叶原位癌）或良性病变。
患有癌症和癌前病变的女性血清（p = 0.0009）的MIS水平低于患有良性疾病的女性血清。
我们的研究结果为MIS与当前乳腺癌风险相关提供了初步证据，这一结论应在更大规模的人群中得到验证。
